Red Blood Cell Health Study Gives Hope for
Individuals with Sickle Cell Disease
For the 100,000 Americans and the millions more around the world
suffering from sickle cell disease, life can be painful and difficult.
Every day, you may be struggling with pain or have to
battle the fear of developing other co-morbid
conditions due to sickle cell anemia.
Functional Fluidics, a biotechnology company specializing in
red blood cell health in Detroit, Michigan, announces that its
biomarkers can help predict sickle cell disease vaso-occlusive
crisis.
Findings of the study were
published in the Blood Journal by
the American Society of
Hematology.
The announcement addresses the need
for well-validated biomarkers to objectively
monitor red blood cell health in individuals
with sickle cell disease and monitor their
drug therapy progress.
Findings from this ELIPSIS study offer medical providers objective red
blood cell biomarkers as tools so they can focus on health maintenance
rather than crisis intervention.
This means that you or your loved one
suffering from sickle cell disease can
monitor your health more effectively and
help your medical providers treat you
earlier and more efficiently.
These findings may also have
therapeutic benefits if you are at high-
risk of a VOC.
Functional Fluidics participated in the study to validate their red blood cell
assays and offer insights on how providers can intervene earlier for high-risk
patients of a vaso-occlusive episode.
Functional Fluidics continues to study it's
biomarkers in Red Blood Cell health to help
patients, clinical providers, and
pharmaceutical companies improve
treatment options for Sickle Cell Disease.
Sickle cell disease may be an
inherited and life-long condition, but
it does not have to rule your life or
define how you live it.
Visit
www.functionalfluidics.
com to learn more.